XML 30 R4.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenues:        
Research and development revenue $ 454,507 $ 262,960 $ 1,247,908 $ 608,576
Costs and expenses:        
Costs of research and development revenue 384,803 243,406 1,034,934 519,331
Research and development 841,343 476,633 2,351,953 1,654,716
Research and development - related party 101,849 288,175 827,632 1,021,573
General and administrative 1,056,196 1,023,606 4,354,941 3,238,145
Foreign currency exchange loss (gain), net 13,727 12,279 24,693 1,921
Total costs and expenses 2,397,918 2,044,099 8,594,153 6,435,686
Loss from operations (1,943,411) (1,781,139) (7,346,245) (5,827,110)
Interest income 245,027 241,644 777,711 647,686
Loss before income taxes (1,698,384) (1,539,495) (6,568,534) (5,179,424)
Provision for income taxes 0 0 900 0
Net loss $ (1,698,384) $ (1,539,495) $ (6,569,434) $ (5,179,424)
Basic and diluted net loss per common share (USD per share) $ (0.06) $ (0.06) $ (0.24) $ (0.19)
Basic and diluted weighted-average common shares outstanding (in shares) 27,181,003 27,774,436 26,909,205 27,996,754